Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

121.90EUR
16 Nov 2018
Change (% chg)

€0.10 (+0.08%)
Prev Close
€121.80
Open
€122.10
Day's High
€123.60
Day's Low
€120.75
Volume
62,183
Avg. Vol
101,321
52-wk High
€155.95
52-wk Low
€97.24

Latest Key Developments (Source: Significant Developments)

Ipsen Delivers Strong Sales Growth Of 20.2%1 For The Q3 2018 And Confirms Full Year Guidance
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG SALES GROWTH OF 20.2%1 FOR THE THIRD QUARTER OF 2018 AND CONFIRMS FULL YEAR GUIDANCE.Q3 2018 GROUP SALES GROWTH OF 20.2%.FULL YEAR 2018 GUIDANCE CONFIRMED.FULL YEAR 2018 GUIDANCE CONFIRMED WITH GROUP SALES GROWTH OF GREATER THAN 19.0%1 AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES.Q3 GROUP SALES EUR 555.9 MILLION VERSUS EUR 470.1 MILLION YEAR AGO.  Full Article

Ipsen Receives Positive CHMP Opinion For Cabometyx
Friday, 21 Sep 2018 

Sept 21 (Reuters) - IPSEN SA ::IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX (CABOZANTINIB) FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).CHMP POSITIVE OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC).  Full Article

Ipsen Raises FY Guidance
Thursday, 26 Jul 2018 

July 26 (Reuters) - Ipsen SA ::H1 OPERATING INCOME EUR 269.7 MILLION VERSUS EUR 176.4 MILLION YEAR AGO.H1 CONSOLIDATED NET PROFIT EUR 197.3 MILLION VERSUS EUR 125.9 MILLION YEAR AGO.UPGRADED FULL YEAR 2018 GUIDANCE OF GROUP SALES GROWTH GREATER THAN 19.0%(1) (VERSUS PRIOR GUIDANCE GREATER THAN 16.0%) AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES (VERSUS PRIOR GUIDANCE GREATER THAN 28.0%).  Full Article

Ipsen’s Cabometyx receives approval from European Commission
Thursday, 17 May 2018 

May 17 (Reuters) - IPSEN SA ::EUROPEAN COMMISSION APPROVES IPSEN’S CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA.EC APPROVED CABOMETYX (CABOZANTINIB) 20, 40, 60 MG FOR FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ARCC.THIS APPROVAL ALLOWS FOR MARKETING OF CABOMETYX (CABOZANTINIB) IN THIS INDICATION IN ALL 28 MEMBER STATES OF EUROPEAN UNION, NORWAY AND ICELAND.  Full Article

Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL.MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO.  Full Article

Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America
Friday, 12 Jan 2018 

Jan 12 (Reuters) - IPSEN SA ::IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA.  Full Article

Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - IPSEN SA ::‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​.‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​.‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​.‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​.  Full Article

Ipsen ‍reports Q3 2017 group sales growth of 22.6%​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - IPSEN SA ::‍Q3 2017 GROUP SALES GROWTH OF 22.6%​.‍FULL YEAR 2017 GUIDANCE CONFIRMED.Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

Ipsen receives validation from European Medicines Agency for application of new indication for Cabometyx
Monday, 11 Sep 2017 

Sept 11 (Reuters) - IPSEN SA ::ANNOUNCED ON FRIDAY, IPSEN RECEIVES VALIDATION FROM EUROPEAN MEDICINES AGENCY FOR THE APPLICATION OF A NEW INDICATION FOR CABOMETYX (CABOZANTINIB) FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN ADULTS.FILING IN FIRST LINE ARCC IS BASED ON THE CABOSUN RESULTS, A PHASE II TRIAL DEMONSTRATING THAT CABOMETYX PROLONGS PROGRESSION-FREE SURVIVAL (PFS) IN TREATMENT-NAIVE PATIENTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RCC COMPARED TO SUNITINIB.  Full Article

Deals of the day-Mergers and acquisitions

Nov 14 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday: